These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 18666459)
41. The introduction of new vaccines into developing countries. IV: Global Access Strategies. Mahoney RT; Krattiger A; Clemens JD; Curtiss R Vaccine; 2007 May; 25(20):4003-11. PubMed ID: 17363119 [TBL] [Abstract][Full Text] [Related]
42. Problems of drug therapy of epilepsy in developing countries. Adamolekun B; Meinardi H Trop Geogr Med; 1990 Apr; 42(2):178-81. PubMed ID: 2260219 [TBL] [Abstract][Full Text] [Related]
43. Funding pharmaceutical innovation through direct tax credits. Lybecker KM; Freeman RA Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650 [TBL] [Abstract][Full Text] [Related]
45. The GO License: only part of the solution. Batson A; Milstien JB Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489 [TBL] [Abstract][Full Text] [Related]
46. Creating reliable pharmaceutical distribution networks and supply chains in African countries: Implications for access to medicines. Tetteh E Res Social Adm Pharm; 2009 Sep; 5(3):286-97. PubMed ID: 19733829 [No Abstract] [Full Text] [Related]
47. Improving access to pharmaceuticals in Brazil and Argentina. Homedes N; Ugalde A Health Policy Plan; 2006 Mar; 21(2):123-31. PubMed ID: 16415339 [TBL] [Abstract][Full Text] [Related]
48. Neglected tropical disease vaccines. Hotez PJ; Brown AS Biologicals; 2009 Jun; 37(3):160-4. PubMed ID: 19278869 [TBL] [Abstract][Full Text] [Related]
49. Drug supply strategies, constraints and prospects in Nigeria. Yusuff KB; Tayo F Afr J Med Med Sci; 2004 Dec; 33(4):389-94. PubMed ID: 15977451 [TBL] [Abstract][Full Text] [Related]
50. The emergence of global health partnerships as facilitators of access to medication in Africa: a narrative policy analysis. Ngoasong MZ Soc Sci Med; 2009 Mar; 68(5):949-56. PubMed ID: 19152991 [TBL] [Abstract][Full Text] [Related]
51. Access to essential drugs. Dev World Bioeth; 2001 Nov; 1(2):89-92. PubMed ID: 12870517 [No Abstract] [Full Text] [Related]
52. No deal in sight on cheap drugs for poor countries. Fleck F Bull World Health Organ; 2003; 81(4):307-8. PubMed ID: 12764500 [No Abstract] [Full Text] [Related]
53. A study of pharmaceutical data exclusivity laws in Latin America: is access to affordable medicine threatened? Cartagena RG; Attaran A Health Law J; 2009; 17():269-96. PubMed ID: 20608321 [No Abstract] [Full Text] [Related]
54. Access to medicines, market failure and market intervention: a tale of two regimes. Williams OD Glob Public Health; 2012; 7 Suppl 2():S127-43. PubMed ID: 23039022 [TBL] [Abstract][Full Text] [Related]
55. Access to medicines report cards. Mullard A Nat Rev Drug Discov; 2016 Nov; 15(12):811. PubMed ID: 27895336 [No Abstract] [Full Text] [Related]
56. Paving the way for the introduction of new vaccines into developing countries. Chabalgoity JA Expert Rev Vaccines; 2005 Apr; 4(2):147-50. PubMed ID: 15889986 [TBL] [Abstract][Full Text] [Related]
57. The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Vitoria M; Granich R; Gilks CF; Gunneberg C; Hosseini M; Were W; Raviglione M; De Cock KM Am J Clin Pathol; 2009 Jun; 131(6):844-8. PubMed ID: 19461091 [TBL] [Abstract][Full Text] [Related]
58. Health research, fair benefits and access to medicines. Lertsithichai P J Med Assoc Thai; 2006 Apr; 89(4):558-64. PubMed ID: 16696406 [TBL] [Abstract][Full Text] [Related]
59. Spurious and counterfeit drugs: a growing industry in the developing world. Gautam CS; Utreja A; Singal GL Postgrad Med J; 2009 May; 85(1003):251-6. PubMed ID: 19520877 [TBL] [Abstract][Full Text] [Related]
60. Vaccines and medicines for the world's poorest. Attempts of global forum for health research should be viewed with optimistic scepticism. MacDonald R BMJ; 2000 Sep; 321(7264):834. PubMed ID: 11009544 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]